A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100

Protocol CRPC2: (AFFIRM) A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Treated with Docetaxel-Based Chemotherapy

Sponsor(s)

Medivation

Principal Investigator(s)Omer Kucuk, MD
Dates8/02/2010 - 8/01/2014